Rezultati pretrage - Corey Lipchik

  • Prikaz rezultata 1 – 4 od 4
Detaljiziraj rezultate
  1. 1
    Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes

    Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes od Nan Song, Katherine L. Pogue‐Geile, Patrick G. Gavin, Greg Yothers, S. Rim Kim, Nicole L. Johnson, Corey Lipchik, Carmen J. Allegra, Nicholas J. Petrelli, Michael J. OʼConnell, Norman Wolmark, Soonmyung Paik

    Izdano 2016
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  2. 2
    Defective Mismatch Repair and Benefit from Bevacizumab for Colon Cancer: Findings from NSABP C-08

    Defective Mismatch Repair and Benefit from Bevacizumab for Colon Cancer: Findings from NSABP C-08 od Kay L. Pogue-Geile, Greg Yothers, Yusuke Taniyama, Noriko Tanaka, Patrick G. Gavin, Linda H. Colangelo, Nicole L. Blackmon, Corey Lipchik, Seong-Rim Kim, Saima Sharif, Carmen J. Allegra, Nicholas J. Petrelli, Michael J. OʼConnell, Norman Wolmark, Soonmyung Paik

    Izdano 2013
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  3. 3
    Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value

    Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value od Patrick G. Gavin, Linda H. Colangelo, Debora Fumagalli, Noriko Tanaka, Matthew Y. Remillard, Greg Yothers, Chungyeul Kim, Yusuke Taniyama, Seung Il Kim, Hyun Joo Choi, Nicole L. Blackmon, Corey Lipchik, Nicholas J. Petrelli, Michael J. OʼConnell, Norman Wolmark, Soonmyung Paik, Kay L. Pogue-Geile

    Izdano 2012
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  4. 4
    Association of Polymorphisms in <i>FCGR2A</i> and <i>FCGR3A</i> With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2–Positive Breast Cancer

    Association of Polymorphisms in <i>FCGR2A</i> and <i>FCGR3A</i> With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2–Positive Breast Cancer od Patrick G. Gavin, Nan Song, S. Rim Kim, Corey Lipchik, Nicole L. Johnson, Hanna Bandos, Melanie Finnigan, Priya Rastogi, Louis Fehrenbacher, Eleftherios P. Mamounas, Sandra M. Swain, D. Lawrence Wickerham, Charles E. Geyer, Jong‐Hyeon Jeong, Joseph P. Costantino, Norman Wolmark, Soonmyung Paik, Kay L. Pogue-Geile

    Izdano 2016
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:

Alati za pretragu: